Phase 3 data from the INDIGO trial support the FDA approval of vorasidenib for select patients with grade 2 astrocytoma or oligodendroglioma.
Approval Alert | Vorasidenib in Grade 2 IDH+ Astrocytoma/Oligodendroglioma
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors
2
Anti-TIGIT Combination Therapy Yields Positive Survival in Gastric Cancers
3
Bridging Radiotherapy Prior to CAR T May Be Safe in R/R Multiple Myeloma
4
Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer
5
